Demand for once-weekly GLP-1 injectable formulations is accelerating across North America, Europe, the GCC, and Asia-Pacific, and India is now the worlds most strategically positioned manufacturing base for cost-efficient, regulation-ready supply
[2] Dulaglutide (Trulicity), another once-weekly injectable GLP-1 agonist, demonstrates a somewhat more favourable gastrointestinal tolerability profile in some studies, with nausea reported in approximately 8-12% of patients at lower doses, though rates increase with higher doses (3
How GLP-1 Agonists Like Ozempic Affect Fertility and Conception Pregnancy is a unique physiological state that significantly alters metabolism and the hormonal environment
But in the case of semaglutide, there is no USP monograph and no assessment of the DMF as part of an application, so bulk manufacturers of semaglutide are, in effect, setting their own standards for what constitutes a quality product